Agios Pharmaceuticals (NASDAQ:AGIO) has been given a $125.00 price objective by equities research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 50.33% from the stock’s current price.
A number of other research analysts have also recently commented on AGIO. BidaskClub cut Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. SunTrust Banks reiterated a “buy” rating and issued a $123.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, July 23rd. Cann reaffirmed a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. Credit Suisse Group set a $95.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 7th. Finally, ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $96.27.
Hot Bank Stocks To Invest In 2019: Cellectis S.A.(CLLS)
Advisors' Opinion:- [By Stephan Byrd]
Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.
Hot Bank Stocks To Invest In 2019: Attunity Ltd.(ATTU)
Advisors' Opinion:- [By Joseph Griffin]
Attunity Ltd (NASDAQ:ATTU) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $12.33.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Attunity (ATTU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on Attunity (ATTU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Hot Bank Stocks To Invest In 2019: ASML Holding N.V.(ASML)
Advisors' Opinion:- [By Ethan Ryder]
ASML (NASDAQ: ASML) and ACM Research (NASDAQ:ACMR) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
- [By Max Byerly]
Get a free copy of the Zacks research report on ASML (ASML)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Jon C. Ogg]
ASML Holding N.V. (NASDAQ: ASML) was down 2.6% to $197.02 on Friday morning. The stock has a 52-week trading range of $126.03 to $216.00 and a consensus analyst target price of $196.81.
- [By Max Byerly]
Front Row Advisors LLC increased its holdings in ASML Holding NV (NASDAQ:ASML) by 15.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,247 shares of the semiconductor company’s stock after purchasing an additional 703 shares during the period. Front Row Advisors LLC’s holdings in ASML were worth $1,042,000 as of its most recent SEC filing.
Orchid Island Capital, Inc., a specialty finance company, invests in residential mortgage-backed securities (RMBS) in the United States. The company's RMBS are backed primarily by single-family residential mortgage loans, referred as Agency RMBS. Its portfolio includes traditional pass-through Agency RMBS; and structured Agency RMBS, including collateralized mortgage obligations, interest only securities, inverse interest only securities, and principal only securities. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2010 and is headquartered in Vero Beach, Florida.
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500庐 company, is an urban office real estate investment trust ("REIT") uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, with a total market capitalization of $17.9 billion and an asset base in North America of 30.2 million SF as of March 31, 2018. The asset base in North America includes 20.8 million RSF of operating properties and 3.5 million RSF of development and redevelopment of new Class A properties currently undergoing construction and pre-construction activities with target delivery dates ranging from 2018 through 2020. Additionally, the asset base in North America includes 5.9 million SF of intermediate-term and future development projects, including 3.6 million SF of intermediate-term development projects. Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science and technology campuses that provide its innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science and technology companies through its venture capital arm. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. For additional information on Alexandria, please visit www.are.com.